Medical researchers have developed the first leukemia therapy that targets a protein, CD123, on the surface of cancer stem cells that drive acute myeloid leukemia, which is an aggressive disease with a poor outcome.
Medical researchers have developed the first leukemia therapy that targets a protein, CD123, on the surface of cancer stem cells that drive acute myeloid leukemia, which is an aggressive disease with a poor outcome.